AKT1 and breast carcinoma: Regarding the molecular effects triggered by cisplatin in breast cancer cells, Wong et al. [35], showed that inhibition of the mTOR, TGFbetaRI, NFκB, PI3K/AKT, and MAPK pathways sensitized basal-like MDA-MB-468 cells to cisplatin treatment.